1995) and defined pejoratively as 'an epidemiological technique for turning a lot of nothing into something' (Milloy, 1995) . According to its critics, meta-analysis begins with Oral contraceptives were introduced into general clinical use scientific studies, sometimes incomplete or disputed. The data in the early 1960s after Enovid ® (G.D.Searle, Skokie, Illinois, from these studies are then run through computer models of USA) gained approval for marketing in the USA by the Food bewildering complexity to produce results of implausible and Drug Administration (FDA). This combination-type oral precision (Shapiro, 1994a) . Rather than continue to talk about contraceptive contained 9.85 mg norethynodrel as the progestmeta-analysis in the abstract, let us see what is actually ogen and 0.15 mg mestranol as the oestrogen, a formulation involved in doing one. that has been superseded by numerous others over the past 35
Since meta-analysis applies statistical methods to synthesize years. At the time of the FDA action, some were concerned results of different studies, the objects of study in a metathat the administration of exogenous hormones, particularly analysis, like that of a traditional review, are the results of oestrogen, might increase a woman's risk of cancer (Hertz and studies. A meta-analysis therefore involves five basic steps: Bailar, 1966; Hertz, 1967 Hertz, , 1969 . Animal studies in the 1920s (i) define the problem; (ii) find the relevant studies that address and 1930s had indicated that ovarian extracts could produce it; (iii) abstract the pertinent information; (iv) analyse the tissue proliferation in the female genital tract (Hertz, 1977) , resulting 'data'; and (v) interpret the results. Petitti (1994) and isolated case reports had appeared in which oestrogen gives an admirably clear and detailed exposition, and advises therapy was suspected of playing a role in the development that a detailed protocol be developed to accomplish each of of cancer of the breast and endometrium (Allaben and Owens, the preceding five steps. 1939; Auchincloss and Haageman, 1940; Parsons and McCall, 1941; Fremont-Smith et al., 1946) . The possibility that steroidal Define the problem contraception might have an effect on the development of cancer in humans, however, lay within the realm of conjecture Of all the questions that might be raised about the consequences until the completion of epidemiological studies over the past of using oral contraceptives, let us take the following to be 20 years. the one of interest: 'Does the use of oral contraceptives affect This paper presents a case history in using meta-analysis to a woman's risk of developing endometrial cancer?' This estimate the risk of one specific cancer, endometrial cancer, question provides a starting point: it identifies in general terms in users of combined oral contraceptives. Before turning to the exposure under consideration, oral contraceptives, and the this, I would like to give the reader some perspective on metaclinical endpoint of interest, endometrial cancer. To make any analysis, a term coined by Glass (1976) .
progress in answering the question, whether by meta-analysis or a traditional narrative review, we need to consider the 'question' in greater detail.
Meta-analysis Use of oral contraceptives-what elements of use should we Meta-analysis is defined as the use of statistical methods to
consider? combine the results of different studies (Last, 1995) . Its Ever use them, regardless of duration? Duration-specific use, first application may have been in 1904, when the English such as use for 1, 2, 4, or 8 years? If duration-specific use is statistician Karl Pearson combined data from British military of interest, should longest continuous use or longest total use tests to conclude that the vaccinations used against enteric be the parameter studied? Do we need to consider separately fever were ineffective (Pearson, 1904) . Since then, metause at an early age, such as in the teens or early 20s? What analysis has been applied to a wide range of issues in the about use initiated later in the reproductive period of life, such social and biomedical sciences, and prescriptions have been as at age 25-29 years or 30-34 years? given for how a meta-analysis ought to be done (e.g. Light and Pillemer, 1984; Petitti, 1994) .
Use of oral contraceptives-do we need to take into account the specific formulation used? Although it is debatable whether meta-analysis has achieved even part of its wider objective of bringing a more systematic Should separate analyses be made by type and dose of oestrogen and progestogen, and by whether the oral contraceptive used approach to the review and synthesis of the scientific literature, one cannot dispute the fact that meta-analysis has been a was sequential, combined, or progestogen only? also looked for additional published studies by reading reviews In the present context, the term risk refers to the probability of the literature and citations in the primary reports. of developing endometrial cancer within some span of time.
A number of important issues are glossed over in the What period of time should be considered: cancer occurrence description given above. Why seek only published studies? within 5 or 10 years of first use? 10-20 years beyond an Why use only MEDLINE for the search? Why read only accumulated 4 years of oral contraceptive use? Should we English-language articles? Since I sought to find all relevant focus on the risk of disease regardless of age at onset, or studies, did my analysis combine studies of lesser 'quality' should we be concerned particularly about disease occurring with those of higher quality? I will return to these questions prior to menopause? After menopause? later in the discussion. The phrase 'affect a woman's risk' implies a comparison; risk of disease in oral contraceptive users compared with Abstract the pertinent information whom? Compared with women who have never used oral For studies giving rise to multiple publications, I used results contraceptives? Compared with women who have used oral from only the most recent report that was pertinent to my contraceptives, but only short-term, such as for 6 months or objective of estimating the effect of duration of use of combined at most 1 year? Compared with women who have used only oral contraceptives and recency of use (time since last use). barrier methods of contraception or 'natural' methods of family Thus, to be eligible for inclusion in my analysis, a study had planning?
to report estimates of risk that were either duration-specific or How will an alteration in risk be measured; as a difference recency-specific. I also abstracted results according to latency in risk (additional or fewer number of cases per 1000 users) (time since first use of combined oral contraceptives) but did or as a ratio of risks (relative risk)? If relative risk is used, not formally incorporate the findings into my meta-analysis. will it be placed in clinical perspective, such as the number With few exceptions, results reported by latency are confounded of additional or fewer cases arising per 1000 users? Will a by duration of use; in other words, time since first use of oral public health perspective be emphasized by estimating the contraceptives will tend to be greater among long-term users. percentage of cases in a population that are 'attributable' to Many epidemiological studies of oral contraception have oral contraceptive use or were 'prevented' by such use? reported estimates of risk or relative risk by 'ever use' of oral Endometrial cancer contraceptives. Unfortunately, the term 'ever use' has little Should specific histological types of endometrial cancer, or biologically plausible meaning in the evaluation of drugs, the stage of disease at time of diagnosis, be considered? Should effects of which are expected on pharmacological grounds the analysis be restricted to invasive disease? Should survival to depend on factors such as dose, formulation, route of after cancer diagnosis be examined? Should atypical hyperplaadministration, duration of use, timing of use etc. Data on sia be considered as an endpoint in future analyses? ever use of oral contraceptives cannot be interpreted because The preceding questions about 'the question' to be addressed 'ever use' has no specific meaning: in one study 'ever use' in a meta-analysis show that the points at issue affect the may correspond to an average duration of 6 months or 2 years, detail with which one reads the literature. For a meta-analysis, while in another it may represent an average duration of 4 or the specific issues also bear directly on the 'data' one needs 5 years. For these reasons I chose to avoid performing a metato abstract from the various reports. Although most of the analysis on 'ever use,' although I did consider results reported above questions have been addressed in the literature, the data for it in interpreting my findings. have not been reported systematically. Thus, a meta-analysis I therefore abstracted from case-control studies the reported will have only limited data available to address most questions.
duration-specific and recency-specific estimates of relative Another consequence is that answers to many of the questions risk along with the corresponding numbers of exposed and unexposed cases and controls. For cohort studies, I abstracted will have to be based on differing subsets of studies. the reported estimates of absolute risk, the numbers of exposed If not, then all is fine; if so, then one wouldn't know which was right. I checked the effect of imputing ϩ2 years in a and unexposed cases, and the person-time at risk (to estimate the numbers of exposed and unexposed controls). Some studies sensitivity analysis (see below). reported both unadjusted and adjusted (for potential conAnalyse the resulting data founding variables) estimates of risk. In these instances I always used the adjusted estimates.
Duration of use Table I shows the studies that I found and included in my meta-analysis. Table II shows some of the studies that I found
The data in Table III are from 11 controlled studies. Figure 1 shows a plot of the 33 estimates of relative risk. Relative risk but excluded because they were ineligible. Tables III and IV give the resulting 'data' that I abstracted from the eligible studies (RR) refers here to the risk of invasive endometrial cancer in women who have used combined oral contraceptives for some shown in Table I invasive disease in users of combined oral contraceptives; a relative risk of 1.4 corresponds to a 40% increase in risk, and as 3-6 months, Ͻ2 years, and 10ϩ years. Since regression analysis was used to estimate relative risk by duration of use, I a relative risk of 0.7 corresponds to a 30% reduction in risk. The period of time for which an alteration in risk occurs will had to assign a specific duration, not an interval, to each estimate of relative risk. For intervals such as 3-6 months or Ͻ2 years, I
be discussed later. The fitted curve shown in Figure 1 was estimated from a used the midpoint (see column headed 'years'). For intervals such as Ͼ5 years or 10ϩ years, I added 2 years to the cut-off weighted regression analysis (Snedecor and Cochran, 1989) based on equation 1 below: point. For example, I used 7 years in the regression analysis for Ͼ5 years oral contraceptive use. The same imputation was used Equation 1: ln(RR dur ) ϭ b 0 ϩ b 1 ϫln(years ϩ 1) for upper categories of recency of use (see Table IV ).
Although imputing ϩ2 years seems reasonable to me, it is The expression 'ln' denotes natural logarithm and years denotes total years of combined oral contraceptive use. The obviously somewhat arbitrary. There is no way to tell from the reports how accurate it might be. One can assign different regression analysis therefore represents a meta-analysis of the data in Table III . In this analysis, each reported estimate of values, such as 0 years, 1 year, or 5 years and see if the estimates of risk from the meta-analysis are materially affected.
relative risk was weighted by its corresponding precision for age, and many were further adjusted for endometrial-cancer risk factors such as adiposity, parity, and use of oestrogen where 'exp' denotes the exponential function. Selected values of RR dur are shown in Figure 1 .
replacement therapy. Figure 1 shows a significant trend of decreasing risk with increasing duration of use of combined Estimates of relative risk by duration of use are correlated within studies because they have a common referent, never oral contraceptives: the risk of endometrial cancer is reduced by an estimated 56% with 4 years of use, by 67% with 8 years Discontinued use of use, and by 72% with 12 years of use (RR dur ϭ 0.44, 0.33, Figure 2 shows a plot of RRs by recency of use of combined 0.28; trend: P Ͻ 0.0001, one-sided).
oral contraceptives. The 'data' are the 19 estimates of relative Four other studies (Ramcharan et al., 1981; WHO Collabor- risk from the six studies shown in Table II . The fitted curve ative Study, 1988; Koumantaki et al., 1989; Vessey and Painter, shown in Figure 2 was estimated from a weighted regression 1995) report reduced risks of endometrial cancer in relation analysis based on equation 1 above, where years was taken to to 'ever use' of combined oral contraceptives (RRs range from be years since last use of combined oral contraceptives (recency 0.1 to 0.6), thereby lending support to the meta-analytical of use). The fitted equation is estimates of relative risk given in Figure 1 . Two investigations and Feinstein, 1979; Trapido, 1983) , however, did not find a protective effect of oral contraceptive use, but these
The results suggest that after stopping oral contraceptive did not distinguish between use of combined oral contraceptives use the risk of endometrial cancer begins to rise from its and sequential oral contraceptives, the latter preparations being reduced levels associated with oral contraception: RR rec ϭ implicated in increasing the risk of endometrial cancer (Weiss 0.33, 0.41, and 0.51 for 5, 10, and 20 years discontinuation and Sayvetz, 1980; Cole, 1980; Henderson et al., 1983) .
respectively; trend (P ϭ 0.011, one-sided). Even 20 years after I checked the effect of imputing ϩ2 years to open-ended stopping use, however, the estimated risk in former users is categories of duration of use by doing separate meta-analyses still almost 50% below that in women who have never used for imputed values of ϩ0 years and ϩ5 years (see Imputing oral contraceptives. values ). When ϩ0 years was used, relative risk was estimated at RR dur ϭ 0.42, 0.32, and 0.27 for 4, 8, and 12 years of use. Interpretation When ϩ5 years was used, relative risk was estimated at There is some evidence to suggest that a residual protective RR dur ϭ 0.46, 0.36, and 0.30 for 4, 8, and 12 years of use.
effect from prior oral contraception will continue throughout Thus, estimates of relative risk by duration of use are not very sensitive to reasonably imputed values. the menopause, a time when the risk of endometrial cancer is greatest. In a study by Stanford et al. (1993) , the risk of invasive I checked the effect of imputing ϩ2 years to the openended categories of recency of use by doing separate metadisease in former users of combined oral contraceptives was reduced by 40% for women age 55-64 years (RR ϭ 0.6, 95%
analyses for imputed values of ϩ0 years and ϩ5 years. When ϩ0 years was added to the upper categories of recency, relative confidence interval: 0.3-1.1); risk was 50% lower in former users age 65ϩ (RR ϭ 0.5, 95% confidence interval: 0.1-1.7).
risk for 5, 10, and 20 years since last use was estimated at RR rec ϭ 0.36, 0.42, and 0.4 respectively. When ϩ5 years was Such a result was anticipated by Key and Pike (1988) , who predicted that 5 years of combined oral contraceptive use added, relative risk was estimated at RR rec ϭ 0.32, 0.40, and 0.51 at 5, 10, and 20 years. Thus, estimates of relative risk by beginning at age 28 years would produce a 60% reduction in lifetime risk. Their estimate was based on the assumption recency of use are not very sensitive to reasonably imputed values. that use of combined oral contraceptives would suppress endometrial mitotic activity to such an extent that 5 years of Latency oral contraception would delay the rise in the age-specific incidence rate of endometrial cancer by 5 years (Pike, 1987) , Two studies [Cancer and Steroid Hormone Study (CASH), 1987; Stanford et al., 1993] have estimated risk in relation to which in turn would produce lower rates of endometrial cancer at older ages.
time since first use (latency), but only one explicitly took into methods (Selvin, 1996) to the values of I oc . For this I assumed that: (i) any duration-related effect of oral contraceptive use Thus, using the results of the meta-analysis, I estimated the cumulative number of cases of invasive endometrial cancer appears immediately, that is, there is no latent effect; (ii) oral contraceptive use begins at age 20 and continues without arising in 100 000 women by duration of use and recency of use of combined oral contraceptives. This was done in interruption for either 4, 8, or 12 years; and (iii) women are at risk of endometrial cancer either for the full span of time two steps.
First, the age-specific incidence rate in women using oral or until they develop the disease. The third assumption is tantamount to assuming there are no competing causes of contraceptives (I oc ) was estimated as a function of women's age, duration of oral contraceptive use, and recency of use by death and no hysterectomies. Table V shows the results of the calculations. means of equation 4 below: Under the assumptions above, the second column of Table  Equation 4 : I oc ϭ I age ϫRR dur ϫRR rec V gives estimates of the total number of women developing endometrial cancer from age 20 through age 54 years in a The term I age denotes the population-based age-specific incidence rate of invasive cancer. Values of I age were assumed cohort of 100 000 US women. Among 100 000 women who never use oral contraceptives, 447 are estimated to develop to equal the rates of uterine corpus cancer (including sites not otherwise specified) reported for US white females and endometrial cancer over 35 years. The corresponding number of cancers estimated to occur in a cohort of 100 000 users of Japanese females in Osaka over the time period 1981 -1985 (Parkin et al., 1992 . These rates were used illustratively combined oral contraceptives is only 283 (4 years of use), 241 (8 years of use), or 213 (12 years of use). Column 4 estimates because the risk of cancer of the uterine corpus is high in the USA (the cumulative incidence through age 74 years is 2.4%) the corresponding cumulative incidence through age 74 years. It shows that for never users, 2.4% (2396 per 100 000) are and low in Japan (0.5%).
The term RR dur in equation 4 represents the estimates of estimated to develop endometrial cancer (97.6% remain free of this disease) through age 74, while the figure is only 1.4% relative risk from equation 2. The term RR rec denotes the effect of recency of use expressed in relation to endometrial-(1417 per 100 000) for women who use combined oral contraceptives for 12 years. cancer risk at the time of discontinuing oral contraceptives. In other words, the estimates of RR rec from equation 3 were
The third and fifth columns of Table V give the results of the analysis applied to Japanese women in Osaka. This too is rescaled to RR ϭ 1.0 at 0 years since last use by applying equation 5 below. a projection of risk, even more so than for US women, because oral contraception is not used in Japan. The analysis is included Equation 5: RR rec ϭ RR rec /RR recϭ0 to give perspective from a 'low cancer incidence' country.
Figures 4 and 5 show graphic representations of the cumulat- Figure 3 shows a plot of the factor [RR dur ϫRR rec ] by age. This is the estimated amount by which the age-specific ive incidence, some of the point estimates of which are Possible refinements to analysis I age was used to estimate the age-specific rate of endometrial cancer in women who never use oral contraceptives. Technically, I age should therefore be adjusted for three factors: first, hysterectomies, which would increase the values of I age at older ages because the number of women 'at risk' of endometrial cancer is actually smaller than the total number of women in the population. Second, adjustment should be made for cancers of the uterine corpus that are not endometrial cancers, which would reduce somewhat the values of I age . Third, adjustment should also be made for use of combined oral contraceptives in the population, which would tend to increase the values of I age . These three adjustments would involve and enough assumptions are already involved in the analysis races, 1983-1987 ; corpus uteri ϩ NOS). NOS ϭ not otherwise specified.
to make the estimates given in Table V subject to some, if not considerable, uncertainty.
Discussion
In view of biological plausibility (King, 1991; Schlesselman and Collins, 1997) , the reduced risk of endometrial cancer associated with use of combined oral contraceptives appears to be due to their use. Factors that could alter the effect, such as formulation, women's body weight, parity, and use of oestrogen replacement therapy, have been discussed elsewhere (Schlesselman and Collins, manuscript submitted). They will not be taken up here, except to say that the magnitude of the protective effect of combined oral contraceptive use seems to depend on duration of use, not on formulation. Meta-analysis can help provide a quantitative perspective (Osaka, 1983- cause-effect depends on other knowledge (Schlesselman, 1987 ; corpus uteri ϩ NOS). NOS ϭ not otherwise specified.
1996). Just as laparoscopy does not eliminate the need for human skills in gynaecological surgery, although it surely represents an advance, so it is with meta-analysis. The use of summarized in the upper panel of Table V . For example, Figure  5 indicates that among 100 000 Japanese women in Osaka statistical methods in literature reviews is an aid to judgment, not a replacement for it. who never use oral contraceptives, an estimated 136 cases of endometrial cancer will arise by age 55 years and an estimated Quality of evidence 473 cases will arise by age 75. Use of oral contraceptives by 100 000 Japanese women for 12 years is estimated to result The conclusions to be drawn from a meta-analysis obviously depend on the individual component studies. Although one in 71 fewer cases of endometrial cancer by age 55 and 202 fewer cases by age 75. By comparison, an estimated 234 fewer would like to separate epidemiology's sheep from its goats, the problem is that apart from detecting obvious errors or cases will occur by age 55 in 100 000 US women using oral contraceptives for 12 years, and 979 fewer cases will occur omissions in the report of a study, or determining that a study is poorly controlled, one often has only a limited basis for by age 75.
The lower two panels in Table V are estimates of upper and judging the study itself because one isn't on site conducting it. Judging the 'quality' of studies based on reading reports of lower 90% confidence limits. These were calculated from upper and lower confidence limits on b 1 for duration of use investigations, and thereby deciding which ought to be included, ignored, or given greater or lesser weight (Chalmers and recency. The lower 90% limits in Table V assume a 'maximum' effect of duration of use (large decline in risk) et al., 1981) , is somewhat like trying to judge whether or not I have a backache and how it should be treated based on coupled with a 'minimum' effect of recency (slow rise in risk after discontinuation). The upper 90% limits assume a reading this discussion. Arguments over the quality of studies, how it should be 'minimum' effect of duration of use (small decline in risk) coupled with a 'maximum' effect of recency (quick rise in determined and what should be made of it, are in fact tangential disputes over what really is at issue, namely, which studies risk after discontinuation).
have the right results? After all, why combine studies reporting studies can be combined, since such studies are inevitably vastly different (Shapiro, 1994a) . If so, then the only point erroneous results with those that have got it right (Slavin, 1995) ? Unfortunately, given the inherent complexity of epidein reviewing the literature is to select the one study that has the right result. miological studies, their problems of measurement, and their imperfect control of potential confounding factors, every
Other pointed criticisms of meta-analysis focus on the fact that it can indeed 'turn a lot of nothing into something.' study, no matter how well done, will have its weaknesses. Furthermore, there will never be any certain means of determinConsistency of undramatic findings, which individually may have been dismissed or given very circumspect interpretations, ing which studies have the 'right' results (Collins and Pinch, 1993) . In this regard, an advantage of using meta-analysis is can give rise to a seemingly precise result in a metaanalysis. Focusing attention on a narrow confidence interval that a reviewer is less likely to be carried away by findings from a single study because they have to be incorporated for an average result, moreover, gives a very distorted perspective. It hides heterogeneity in results within and formally into a body of existing literature. Exactly how this is done, however, is itself the subject of some dispute (Fleiss among studies, and obscures some of the limitations of non-experimental studies (Shapiro, 1994a) . In this regard, and Gross, 1991; Thompson and Pocock, 1991; Slavin, 1995) . For example, I weighted the reported relative risks from all part of the underlying problem is misinterpreting statistical estimates of precision (Greenland, 1990 ). In particular, pertinent studies in proportion to their estimated precision, which depends on study size. I deliberately did not take into confidence intervals and standard errors for the result of a single study do not account for bias or systematic error account the 'quality' of studies.
Weighting by estimated precision does not account for within that study. This problem was noted 25 years ago (Youden, 1972) in a review of studies over the period possible bias or heterogeneity in results. As a consequence, large studies, which can be biased just as much as small 1895-1961 measuring the astronomical unit, which is the mean distance between the earth and the sun. Each ones, are probably given too much weight (Colditz et al., 1995) . The same remark applies to heterogeneity. For investigator's estimate fell outside the limits of error reported by the immediate predecessor. If physics has problems with example, suppose that I want to determine the average height of two men, Smith and Jones. Smith is obviously systematic errors, then why not epidemiology? tall and Jones is clearly short. Even though I may have Heterogeneity of findings measured Smith's height six times and Jones's only twice, I should give equal weight to the average height determined Some lament the fact that meta-analyses often combine 'obviously disparate results into summary estimates' (e.g. for each man when I calculate an average height for the two of them. I should not give the average height for Smith Greenland, 1994; Shapiro, 1994b) . Disparate results are combined all of the time, even in analysing data from a greater weight, simply because it was determined more precisely.
single, randomized clinical trial. Rarely is a treatment 100% effective and rarely will a drug produce identical results in Limits of subjectivity the same patient, much less different patients. The results of treatment in groups of individuals, some of whom One alternative to meta-analysis is the traditional review of the literature based on thoughtful critique by one or 'respond' while others do not, are justifiably combined to yield an estimate of average treatment effect. Only the naive more knowledgeable experts. Results of some studies are emphasized while others are dismissed. This approach rests reader will infer from this that a treatment's effectiveness is invariable, applying in constant fashion to all persons on subjectivity, but it could, and possibly often does, lead to excellent results. Meta-analysis, for all its many problems, under all conditions. The question thus becomes one of interaction or effect modification: in what situations are the provides a means of determining subjectivity's limits. For example, suppose one takes issue with my inclusion of data estimates of risk or treatment effect materially altered? To answer this question, which is commonly posed in clinical from the cohort study reported by Beral et al. (1988) , arguing that the results could have been based in part on practice, one needs a point of departure, which might as well be the 'synthetic' estimate of effect referred to above sequential and progestogen-only oral contraceptives. If the data of Beral et al. (1988) are excluded, the meta-analytical that some regard as being potentially misleading.
Consider the results shown in Figure 1 . Imagine that all estimates of relative risk by duration of use are scarcely affected: RR dur ϭ 0.45, 0.33, and 0.28 for 4, 8, and 12 of the reported estimates of relative risk fell exactly along the fitted regression curve. In one sense there would be no years respectively (see Figure 1) . Suppose one also objects to my inclusion of data from the study by Weiss and heterogeneity whatsoever: knowing the duration of use of combined oral contraceptives would allow one to determine Sayvetz (1980) , arguing that the referent group in that study was not women who had never used oral contraceptives, but precisely the relative risk of endometrial cancer. The absence of heterogeneity in this situation would apply only to rather women who either had never used oral contraceptives or had used them for Ͻ1 year. If all of the data from Beral groups of individuals, however; considerable heterogeneity in individual outcomes within groups would still remain. et al. (1988) and Weiss and Sayvetz (1980) are excluded, the meta-analytical estimates of relative risk by duration of Let me explain. Suppose that the relative risk of endometrial cancer were use are identical to those given in Figure 1 . The extreme position, of course, is that none of the data from observational exactly RR ϭ 0.33 in women using combined oral contraceptives for 8 years, and that six different epidemiologamong the results for groups of persons. Thus, one might ask why all of the estimates of relative risk don't fall ical studies had precisely the same result. This would beg a question: 'How do such findings apply to my patient, exactly along the regression curve in Figure 1 ? Is the variability in the estimates of relative risk about the fitted Mrs Smith, who has used combined oral contraceptives for 8 years?' The honest answer is that one really cannot say regression curve more than one would expect by chance? If the results do vary more than expected by chance, then what the result of such use will be in Mrs Smith. All one can say is that in a group of women using combined oral what is the explanation? At this point one begins to embark on a study of the studies, seeking 'causes' for the variability contraceptives for 8 years, the number developing endometrial cancer should be reduced by 67% in comparison with a in their findings. Whether this is a productive endeavor depends on your objectives, on the circumstances, and on group of women who never use combined oral contraceptives. In other words, since the relative risk is not exactly zero, the outcome. For example, breast cancer in relation to use of oral contraceptives has been a contentious issue over the some women will develop endometrial cancer despite their use of oral contraception. We therefore cannot determine past 15 years, with some studies showing substantial, statistically significant increased risks (e.g. Pike et al., 1983 ; with certainty the effect of oral contraceptive use in any particular woman because we don't know what would have Meirik et al., 1986; UK National Case Control Study Group, 1989 ) and others showing little or no effect (e.g. Cancer occurred to her in the absence of use.
To be clear about this, consider two possible outcomes. and Steroid Hormone Study, 1987; Paul et al., 1990; WHO Collaborative Study, 1990 ). Since there is considerable First, imagine that Mrs Smith uses combined oral contraceptives and does not develop endometrial cancer at any point heterogeneity in the results for different studies, one might want to know the reason(s). Thus, one might ask whether in her life. One possible interpretation is that Mrs Smith would never have developed endometrial cancer in the the results differed materially by the design of studies (cohort, or case-control), or by the years in which the cases absence of oral contraceptive use, and therefore oral contraceptives played no role whatsoever in preventing the were accrued, or by the type of oral contraceptive used by most of the women, or by the average age of the cases, disease. Another interpretation is that Mrs Smith's use of combined oral contraceptives actually prevented an endometetc, etc. The analyses could be based on 'meta-regression,' in which study characteristics could be used as covariates rial cancer that would have occurred in the absence of use. Since the lifetime risk of endometrial cancer is small, some in a regression analysis (e.g. Berlin et al., 1993; Greenland, 1987) . To my knowledge there has never been a satisfactory may favour the first interpretation over the second unless a very strong family history of the disease is present. However, explanation for the discrepancies among the studies of breast cancer, despite the fact that extensive (unpublished results) there is no means to prove that one or the other explanation is correct in this particular instance (Schlesselman, 1987) .
efforts were made in the mid-1980s to make the 'positive studies negative and the negative studies positive' through Next, imagine that Mrs. Smith develops endometrial cancer despite her use of combined oral contraceptives for collaborative analyses of the original data. Recent collaborative analyses, however, which extend well beyond the initial 8 years. One perverse interpretation would be that in this particular instance use of oral contraceptives actually caused disputants, attempt to set the record straight (Collaborative Group, 1996) . Mrs. Smith's disease. This would obviously fly in the face of the epidemiological evidence, which indicates that Although there is widespread advice to use statistical methods to formally test for heterogeneity, I believe that combined oral contraceptive use substantially reduces endometrial cancer risk, so the explanation given would have to for epidemiological studies one can safely assume that heterogeneity always exists, regardless of the results of depend on a line of biological reasoning that would either have to challenge the generally accepted rationale for a statistical tests of significance. Whether an attempt to discover the reason(s) for heterogeneity is scientific wisdom protective effect, or offer an explanation as to why it didn't apply in the present instance. A second interpretation could or folly depends not only on the extent of heterogeneity, but also on whether finding reason(s) for it will advance be that Mrs Smith's use of oral contraceptives was truly protective despite her development of cancer because oral knowledge to an important degree. contraceptive use delayed the onset of a cancer that would Publication bias have appeared at an earlier age in the absence of use. A third interpretation could be that in this particular instance
The objective I set was to review the published Englishlanguage literature pertinent to use of combined oral oral contraceptive use had no effect whatsoever: Mrs Smith was 'destined' to develop cancer and her use of oral contraceptives and endometrial cancer. Eligible studies had to be internally controlled. That is, by design they had to contraceptives was inconsequential in this regard. Once again, there is no means to prove that one of the preceding be a cohort study, a case-control study, or a controlled clinical trial. explanations is correct and the others are false, although one might be able to offer a chain of reasoning to give
The restriction to English-language studies with citations accessible through MEDLINE may have resulted in my more credence to one of the interpretations.
Concern about heterogeneity in meta-analyses is usually missing some reports. Anyone who has searched the biomedical literature with MEDLINE quickly realizes that raised not in terms of differences among individuals, which I have been discussing, but rather in terms of variability it is neither 100% sensitive nor 100% specific in finding 'relevant' studies. First, not all journals are covered by nonetheless appear in a meta-analysis? I think not. Studies that are published in the medical literature are available for MEDLINE, and MEDLINE does not cover books, for which there is presently no computerized index for searching public scrutiny. They form the basis of informed debate, conjecture, and decision making by physicians, patients, articles or material within them. This implies that some studies can be missed because they were published only in regulatory agencies, and others. To varying degrees, such papers undergo and withstand the criticisms of peer review. a book or in a secondary journal. Another problem is that some articles that are pertinent to your review may not
The fact that publication bias can occur serves to emphasize that much of scientific knowledge is provisional. Whether have been indexed in a way that your search strategy can find them. A larger problem is that a search can turn up unpublished studies, or studies that have yet to be done, can add to or alter the results of any review is an inherent literally hundreds of references, only a few of which are relevant to your specific aims. The only way to know for limitation of our work. sure is to read each article, provided you have the time and resources to track down every one. Many articles have Summary and conclusions on-line abstracts, however, so one can often tell from this, or from the title alone, that a paper is unlikely to be relevant.
Meta-analysis helps one place qualitative statements in As for my restriction to studies published in English, quantitative context. Thus, a review of the epidemiological problems could arise in applying my meta-analysis if oral literature indicates that oral contraception with products contraceptives have different effects for metabolic or other containing both oestrogen and progestogen reduces the risk reasons in women of different nationalities, and if studies of endometrial cancer. There also appears to be a residual of such women are reported predominantly in languages protective effect that continues long after oral contraceptive other than English. Of course, if one is specifically interested use is stopped. The results in Table V suggest that users in the effects of oral contraceptive use in mainland Chinese of combined oral contraceptives are spared a proportionately or in the Thai, then one needs to find the pertinent literature.
large number of endometrial cancers. The absolute numbers An even larger, virtually insolvable problem has been are relatively small, however. The absolute reduction in risk raised with regard to reviewing only published studies. It is therefore unlikely to be of material consequence to the is the 'file drawer problem ' (Rosenthal, 1979) , which is a individual. For example, the probability of remaining free catchword for publication bias. This refers to the very real of endometrial cancer through age 74 is estimated to be possibility that some studies which do not show expected 97.6% for a US woman. Use of combined oral contraceptives results, or which have small sample sizes or 'non-significant' for 12 years is projected to increase that probability by findings, might not have been published or even completed 1.0%, to 98.6%. (e.g., Koren et al., 1989; Easterbrook et al., 1991; Szklo, 1991; Cook et al., 1993; Petitti, 1994) . Such studies or Acknowledgments fragments of studies could simply have been stuffed into I thank J.A.Collins and G.G.Schwartz for their suggestions to the file drawer.
improve this paper. This should not be construed to imply their If the problem with unpublished studies were only small full agreement with all that is written. sample size, then excluding such studies would be irrelevant to the point estimates of effect: although the precision of a meta-analytical estimate might be reduced, the estimate itself References would not be biased up or down simply because data from Allaben, G.R. and Owens, S.E. (1939) Adenocarcinoma of the breast coincidental with strenuous estrogen therapy. J. Am. Med. Assoc., 112,  large studies were covered in a review. Thus, the more 1933-1934. serious concern is with large (sample size) unpublished 
